"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Active surveillance is noninferior to BCG induction therapy for invasive relapse-free survival in patients with high-grade T1 bladder cancer with no residual tumor on second TURBT. For patients with ...

The PD-1 inhibitor sasanlimab showed anti-tumor activity and manageable safety in combination with BCG induction and maintenance compared with standard of care in patients with BCG-naïve high-risk ...

Urothelial cancers that are either non-invasive papillary (Ta), carcinoma in situ (CIS) flat tumors, or invade the subepithelial connective tissue (T1) are collectively termed non-muscle-invasive ...

Use of 2 sequential induction courses of BCG for high-risk NMIBC rather than standard induction with maintenance therapy showed an excellent response rate. A novel strategy for using bacillus Calmette ...

Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC). This is an ASCO Meeting ...

BCG therapy for NMIBC is associated with significant symptoms and side effects, but combining it with chemotherapy reduces these effects. BCG induction with maintenance is less toxic than induction ...

SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...